NCT05521269View on ClinicalTrials.gov

Dose Study of ANX1502 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

135

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

November 19, 2024

Study Completion Date

November 19, 2024

Conditions

Healthy

Interventions

DRUG

ANX1502

ANX1502 is a prodrug of ANX1439.

DRUG

Placebo

Placebo comparator.

Trial Locations (1)

Unknown

Annexon Investigational Site 01, Groningen

All Listed Sponsors

lead

Annexon, Inc.

INDUSTRY